14 These AEs can significantly impact a patients quality of life, leading to decreased adherence, limitation of dose escalations, and, in some cases, treatment discontinuation
This makes it significantly more effective, even at lower doses, than standard forms
Current professional guidance on how far ahead to stop varies, so this is a conversation to have early rather than the day before
Additional considerations include: Concurrent medications : Certain drugs (including some antiretrovirals, immunosuppressants, and diuretics) may increase pancreatitis risk Structural pancreatic abnormalities : Pancreatic divisum or other anatomical variants may predispose to inflammation Family history : Hereditary pancreatitis syndromes, though rare, substantially elevate risk NICE guidance (NG28) on type 2 diabetes management emphasises individualised treatment selection based on patient characteristics and comorbidities
not approved For the combined research planning context, see the Wolverine Stack guide